RaySearch Laboratories AB has received regulatory market approval by the Chinese regulatory agency CFDA for RaySearch’s treatment planning system RayStation®. The approval means that RayStation® can now be sold on the Chinese market.
Since November 2011, RaySearch is represented on the Chinese market by the distributor Kang Li Da Trading Corporation, based in Beijing. Kang Li Da has so far been active in pre-marketing activities and in the regulatory process to get CFDA approval. Now when market approval has been secured Kang Li Da will be fully responsible for marketing, sales and service for RayStation® on the entire Chinese market.
China is one of the largest radiation therapy markets globally with approximately 1300 radiation therapy clinics. There is a strong focus on improving healthcare so the radiation therapy sector is growing very rapidly and the number of clinics is expected to increase to 2,000 in less than five years.
“China is the fastest growing radiation therapy market so this approval is of great strategic importance to us. Together with Kang Li Da we have already been active on the Chinese market for more than a year and a half so we know there is a large interest for RayStation® in China. We are therefore very excited that we can now start offering RayStation® to the Chinese clinics”, says Johan Löf, CEO of RaySearch.
RayStation® integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch’s products are mainly sold through license agreements with leading partners such as Philips, Nucletron, IBA, Varian, Accuray and Brainlab. To date, 15 products have been launched through partners and RaySearch’s software is used at over 2,000 clinics in more than 30 countries. In addition, RaySearch offers the proprietary treatment planning system RayStation® directly to clinics. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.
For more information about RaySearch, visit www.raysearchlabs.com
For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB
Telephone: +46 (0)8-545 061 30